Sanara Medtech Inc (SMTI) financials
Sanara Medtech revenue and earnings by year
Sanara Medtech's revenue was $103 million in the fiscal year to December 31, 2025, up 19.0% from the year before. Net income was -$37.6 million, -36.4% of revenue. Since the fiscal year to December 31, 2017, revenue has grown 41.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 9 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 103 | 87 | 65 | 46 | 24 | 16 | 12 | 6 | 6 |
| Revenue growth | 19.0% | 33.4% | 41.8% | 89.9% | 54.9% | 32.5% | 101.6% | -7.4% | — |
| Gross profit | 96 | 79 | 57 | 39 | 22 | 14 | 11 | 5 | 5 |
| Gross margin | 92.7% | 90.6% | 87.9% | 86.1% | 90.4% | 89.6% | 89.7% | 91.3% | 87.2% |
| Operating income | 7 | 1 | -8 | -12 | -7 | -5 | -3 | -1 | 0 |
| Operating margin | 7.1% | 1.4% | -11.8% | -26.7% | -30.6% | -32.3% | -23.3% | -8.6% | 1.9% |
| Net income | -38 | -10 | -4 | -8 | -8 | -4 | -3 | -1 | 0 |
| Net margin | -36.4% | -11.2% | -6.6% | -17.3% | -32.8% | -27.9% | -23.9% | -10.3% | 5.3% |
| Diluted EPS | -$4.36 | -$1.14 | -$0.52 | -$1.01 | -$1.08 | -$0.76 | -$1.32 | — | — |
| Free cash flow | 2 | -0 | -4 | -6 | -5 | -5 | -2 | 0 | -0 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open SMTI in Markets.
How Sanara Medtech makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Soft Tissue Repair Products | $25.2M | 89.7% |
| Bone Fusion Products | $2.89M | 10.3% |
See also: SMTI returns
No forecast, no recommendation. This page describes Sanara Medtech Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.